Oncology Biosimilars Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Monoclonal Antibodies, Immunomodulators, Others); Cancer Type (Lung Cancer, Colorectal Cancer, Cervical Cancer, Breast Cancer, Stomach Cancer, Brain Cancer, Others)

Report Code: TIPRE00002766 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET OVERVIEW

Biosimilars are the fastest-growing class of therapeutic products across the globe. Biosimilars are biologics that serves as interchangeable products offering additional treatment options to a branded drug counterpart, potentially reducing the cost of the prescribed biologics. The biosimilar therapies have been for chronic disease management and supportive care since a few years, however the use of these biosimilars are expected to be applied soon for treatment of various types of cancers referred to as oncology biosimilars.

MARKET SCOPE

The "Global Oncology Biosimilars Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the oncology biosimilars market with detailed market segmentation by product, cancer type, and geography. The report provides key statistics on the market status of the leading oncology biosimilars market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

  •   Based on product, the global oncology biosimilars market is segmented into monoclonal antibodies, immunomodulators, other products.
  •   On the basis of cancer type, the market is segmented into lung cancer, colorectal cancer, cervical cancer, breast cancer, stomach cancer, brain cancer, others.

MARKET DYNAMICS
Drivers:

  •   Rise in the prevalence of cancer
  •   Growing demand for innovative therapies
  •   Loss of patent exclusivity of the leading biologic drugs

Restraints:

  •   Stringent Regulatory Process

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The Oncology Biosimilars market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the marketduring the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the market in these regions.

IMPACT OF COVID-19 ON ONCOLOGY BIOSIMILARS MARKET

The COVID-19 pandemic is imposing great challenges on the oncology biosimilars market and pharmaceutical companies focused on biosimilar development. The delay in the FDA approval of non-COVID therapeutics has hampered the product approvals and launches. Also, many clinical trials have been postponed minimizing the infection of COVID-19 situation and, most of the pipeline products are exhibiting a slow pace of research and development activities. Thus, COVID-19 is negatively impacting the growth of the market.
?

MARKET PLAYERS

The report covers key developments in the oncology biosimilars market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from oncology biosimilars market are anticipated to lucrative growth opportunities in the future with the rising demand for Oncology Biosimilars market in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the oncology biosimilars market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

  •   Biocon
  •   Celltrion Inc.
  •   Dr. Reddy's Laboratories Ltd.
  •   Amgen Inc.
  •   Intas Pharmaceuticals Ltd.
  •   Pfizer Inc.
  •   Sandoz International GmbH (A Novartis Division)
  •   Teva Pharmaceutical Industries Ltd.
  •   Mylan N.V.
  •   BIOCAD

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Oncology Biosimilars Market - By Product
1.3.2 Oncology Biosimilars Market - By Cancer Type
1.3.3 Oncology Biosimilars Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ONCOLOGY BIOSIMILARS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ONCOLOGY BIOSIMILARS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ONCOLOGY BIOSIMILARS MARKET - GLOBAL MARKET ANALYSIS
6.1. ONCOLOGY BIOSIMILARS - GLOBAL MARKET OVERVIEW
6.2. ONCOLOGY BIOSIMILARS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. ONCOLOGY BIOSIMILARS MARKET - REVENUE AND FORECASTS TO 2028 - PRODUCT
7.1. OVERVIEW
7.2. PRODUCT MARKET FORECASTS AND ANALYSIS
7.3. MONOCLONAL ANTIBODIES
7.3.1. Overview
7.3.2. Monoclonal Antibodies Market Forecast and Analysis
7.4. IMMUNOMODULATORS
7.4.1. Overview
7.4.2. Immunomodulators Market Forecast and Analysis
7.5. OTHERS
7.5.1. Overview
7.5.2. Others Market Forecast and Analysis
8. ONCOLOGY BIOSIMILARS MARKET - REVENUE AND FORECASTS TO 2028 - CANCER TYPE
8.1. OVERVIEW
8.2. CANCER TYPE MARKET FORECASTS AND ANALYSIS
8.3. LUNG CANCER
8.3.1. Overview
8.3.2. Lung Cancer Market Forecast and Analysis
8.4. COLORECTAL CANCER
8.4.1. Overview
8.4.2. Colorectal Cancer Market Forecast and Analysis
8.5. CERVICAL CANCER
8.5.1. Overview
8.5.2. Cervical Cancer Market Forecast and Analysis
8.6. BREAST CANCER
8.6.1. Overview
8.6.2. Breast Cancer Market Forecast and Analysis
8.7. STOMACH CANCER
8.7.1. Overview
8.7.2. Stomach Cancer Market Forecast and Analysis
8.8. BRAIN CANCER
8.8.1. Overview
8.8.2. Brain Cancer Market Forecast and Analysis
8.9. OTHERS
8.9.1. Overview
8.9.2. Others Market Forecast and Analysis
9. ONCOLOGY BIOSIMILARS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Oncology Biosimilars Market Overview
9.1.2 North America Oncology Biosimilars Market Forecasts and Analysis
9.1.3 North America Oncology Biosimilars Market Forecasts and Analysis - By Product
9.1.4 North America Oncology Biosimilars Market Forecasts and Analysis - By Cancer Type
9.1.5 North America Oncology Biosimilars Market Forecasts and Analysis - By Countries
9.1.5.1 United States Oncology Biosimilars Market
9.1.5.1.1 United States Oncology Biosimilars Market by Product
9.1.5.1.2 United States Oncology Biosimilars Market by Cancer Type
9.1.5.2 Canada Oncology Biosimilars Market
9.1.5.2.1 Canada Oncology Biosimilars Market by Product
9.1.5.2.2 Canada Oncology Biosimilars Market by Cancer Type
9.1.5.3 Mexico Oncology Biosimilars Market
9.1.5.3.1 Mexico Oncology Biosimilars Market by Product
9.1.5.3.2 Mexico Oncology Biosimilars Market by Cancer Type
9.2. EUROPE
9.2.1 Europe Oncology Biosimilars Market Overview
9.2.2 Europe Oncology Biosimilars Market Forecasts and Analysis
9.2.3 Europe Oncology Biosimilars Market Forecasts and Analysis - By Product
9.2.4 Europe Oncology Biosimilars Market Forecasts and Analysis - By Cancer Type
9.2.5 Europe Oncology Biosimilars Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Oncology Biosimilars Market
9.2.5.1.1 Germany Oncology Biosimilars Market by Product
9.2.5.1.2 Germany Oncology Biosimilars Market by Cancer Type
9.2.5.2 France Oncology Biosimilars Market
9.2.5.2.1 France Oncology Biosimilars Market by Product
9.2.5.2.2 France Oncology Biosimilars Market by Cancer Type
9.2.5.3 Italy Oncology Biosimilars Market
9.2.5.3.1 Italy Oncology Biosimilars Market by Product
9.2.5.3.2 Italy Oncology Biosimilars Market by Cancer Type
9.2.5.4 Spain Oncology Biosimilars Market
9.2.5.4.1 Spain Oncology Biosimilars Market by Product
9.2.5.4.2 Spain Oncology Biosimilars Market by Cancer Type
9.2.5.5 United Kingdom Oncology Biosimilars Market
9.2.5.5.1 United Kingdom Oncology Biosimilars Market by Product
9.2.5.5.2 United Kingdom Oncology Biosimilars Market by Cancer Type
9.2.5.6 Rest of Europe Oncology Biosimilars Market
9.2.5.6.1 Rest of Europe Oncology Biosimilars Market by Product
9.2.5.6.2 Rest of Europe Oncology Biosimilars Market by Cancer Type
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Oncology Biosimilars Market Overview
9.3.2 Asia-Pacific Oncology Biosimilars Market Forecasts and Analysis
9.3.3 Asia-Pacific Oncology Biosimilars Market Forecasts and Analysis - By Product
9.3.4 Asia-Pacific Oncology Biosimilars Market Forecasts and Analysis - By Cancer Type
9.3.5 Asia-Pacific Oncology Biosimilars Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Oncology Biosimilars Market
9.3.5.1.1 Australia Oncology Biosimilars Market by Product
9.3.5.1.2 Australia Oncology Biosimilars Market by Cancer Type
9.3.5.2 China Oncology Biosimilars Market
9.3.5.2.1 China Oncology Biosimilars Market by Product
9.3.5.2.2 China Oncology Biosimilars Market by Cancer Type
9.3.5.3 India Oncology Biosimilars Market
9.3.5.3.1 India Oncology Biosimilars Market by Product
9.3.5.3.2 India Oncology Biosimilars Market by Cancer Type
9.3.5.4 Japan Oncology Biosimilars Market
9.3.5.4.1 Japan Oncology Biosimilars Market by Product
9.3.5.4.2 Japan Oncology Biosimilars Market by Cancer Type
9.3.5.5 South Korea Oncology Biosimilars Market
9.3.5.5.1 South Korea Oncology Biosimilars Market by Product
9.3.5.5.2 South Korea Oncology Biosimilars Market by Cancer Type
9.3.5.6 Rest of Asia-Pacific Oncology Biosimilars Market
9.3.5.6.1 Rest of Asia-Pacific Oncology Biosimilars Market by Product
9.3.5.6.2 Rest of Asia-Pacific Oncology Biosimilars Market by Cancer Type
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Oncology Biosimilars Market Overview
9.4.2 Middle East and Africa Oncology Biosimilars Market Forecasts and Analysis
9.4.3 Middle East and Africa Oncology Biosimilars Market Forecasts and Analysis - By Product
9.4.4 Middle East and Africa Oncology Biosimilars Market Forecasts and Analysis - By Cancer Type
9.4.5 Middle East and Africa Oncology Biosimilars Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Oncology Biosimilars Market
9.4.5.1.1 South Africa Oncology Biosimilars Market by Product
9.4.5.1.2 South Africa Oncology Biosimilars Market by Cancer Type
9.4.5.2 Saudi Arabia Oncology Biosimilars Market
9.4.5.2.1 Saudi Arabia Oncology Biosimilars Market by Product
9.4.5.2.2 Saudi Arabia Oncology Biosimilars Market by Cancer Type
9.4.5.3 U.A.E Oncology Biosimilars Market
9.4.5.3.1 U.A.E Oncology Biosimilars Market by Product
9.4.5.3.2 U.A.E Oncology Biosimilars Market by Cancer Type
9.4.5.4 Rest of Middle East and Africa Oncology Biosimilars Market
9.4.5.4.1 Rest of Middle East and Africa Oncology Biosimilars Market by Product
9.4.5.4.2 Rest of Middle East and Africa Oncology Biosimilars Market by Cancer Type
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Oncology Biosimilars Market Overview
9.5.2 South and Central America Oncology Biosimilars Market Forecasts and Analysis
9.5.3 South and Central America Oncology Biosimilars Market Forecasts and Analysis - By Product
9.5.4 South and Central America Oncology Biosimilars Market Forecasts and Analysis - By Cancer Type
9.5.5 South and Central America Oncology Biosimilars Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Oncology Biosimilars Market
9.5.5.1.1 Brazil Oncology Biosimilars Market by Product
9.5.5.1.2 Brazil Oncology Biosimilars Market by Cancer Type
9.5.5.2 Argentina Oncology Biosimilars Market
9.5.5.2.1 Argentina Oncology Biosimilars Market by Product
9.5.5.2.2 Argentina Oncology Biosimilars Market by Cancer Type
9.5.5.3 Rest of South and Central America Oncology Biosimilars Market
9.5.5.3.1 Rest of South and Central America Oncology Biosimilars Market by Product
9.5.5.3.2 Rest of South and Central America Oncology Biosimilars Market by Cancer Type
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL ONCOLOGY BIOSIMILARS MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. ONCOLOGY BIOSIMILARS MARKET, KEY COMPANY PROFILES
12.1. BIOCON
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. CELLTRION INC.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. DR. REDDY'S LABORATORIES LTD.
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. AMGEN INC.
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. INTAS PHARMACEUTICALS LTD.
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. PFIZER INC.
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. SANDOZ INTERNATIONAL GMBH (A NOVARTIS DIVISION)
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. TEVA PHARMACEUTICAL INDUSTRIES LTD.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. MYLAN N.V.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. BIOCAD
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS

The List of Companies

1. Biocon
2. Celltrion Inc.
3. Dr. Reddy's Laboratories Ltd.
4. Amgen Inc.
5. Intas Pharmaceuticals Ltd.
6. Pfizer Inc.
7. Sandoz International GmbH (A Novartis Division)
8. Teva Pharmaceutical Industries Ltd.
9. Mylan N.V.
10. BIOCAD
TIPRE00002766
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking